Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on pancreatic cancer market provides in-depth analysis of segments and sub-segments in the global as well as regional pancreatic cancer market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional pancreatic cancer market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global pancreatic cancer market.
Pancreatic cancer is a type of cancer that originates in the pancreas, an organ located in the abdomen behind the stomach. It occurs when aberrant pancreatic cells begin to multiply and develop out of control, eventually forming a tumor. Because it frequently remains unnoticed until it has advanced stages and spread to other organs, pancreatic cancer is regarded as a very fatal and severe condition. Abdominal pain, weight loss, jaundice, digestive issues, and weariness are a few of its symptoms. Surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy are among the available treatments for pancreatic cancer. The market for pancreatic cancer propels due to rising rates of Pancreatic Cancer Cases and rising government policies toward improving healthcare infrastructure.
The increasing incidence and prevalence of pancreatic cancer cases worldwide are major factors driving the growth of the pancreatic cancer market. Pancreatic cancer is majorly caused due to rising diabetes rates among adults, rising obesity in youngsters due to unhealthy lifestyles, and exposure to certain chemicals or toxins. For instance, World Health Organization (WHO) estimated pancreatic cancer as the third leading cancer-related cause of death in people of all ages for both sexes in the USA, Germany, Italy, Austria, Czechia, Finland, Hungary, Malta, Spain, and Switzerland in 2020. Therefore, with rising rates of diagnosis, there is a growing demand for advanced diagnostic tools, effective treatment options, and supportive care services. Advancements in diagnostic technology, such as imaging techniques and biomarker testing, enable earlier and more accurate detection of pancreatic cancer, leading to improved patient outcomes. However, the high cost of pancreatic cancer treatment, including surgeries, chemotherapy, radiation therapy, and targeted therapies, can create financial burdens for patients from lower to middle-income groups. Additionally, these treatments often come with significant side effects, such as nausea, fatigue, loss of appetite, and hair loss, which can impact patients' quality of life. The cost and side effects associated with treatment may potentially hamper the growth of the pancreatic cancer market. For instance, according to the American Society of Clinical Oncology. An entire six-month course of chemotherapy costs approximately USD 23,500. The cost of the medication Erlotinib together brings the total cost of care to about USD 45,000.
The global pancreatic cancer Market is segmented into Asia Pacific, North America, Europe, the Middle East & Africa, and South America. Among the regions, North America is anticipated to dominate the pancreatic cancer market during the forecast period. The expansion of the market in the area is attributed to the existence of cutting-edge medical facilities and the implementation of new technology for diagnostics. Along with these factors, the presence of well-established competitors in the area and the rising prevalence of the ailment across North America are fostering the expansion of the pancreatic market there.
| Report Coverage | Details |
|---|---|
| Market Size in 2022 | USD 2448.9 Million |
| Market Size by 2030 | USD 7114.4 Million |
| Growth Rate from 2023 to 2030 | CAGR of 12.5% |
| Largest Market | North America |
| No. of Pages | 100 |
| Market Drivers |
|
| Market Segmentation | By Type, By Treatment Type, By Diagnosis, By Route of Administration, By End User, and By Distribution Channel |
| Regional Scope | North America, Europe, Asia Pacific, and RoW |
The report on global pancreatic cancer market covers segments such as type, treatment type, diagnosis, route of administration, end user, and distribution channel. On the basis of type, the sub-markets include exocrine, and endocrine. On the basis of treatment type, the sub-markets include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. On the basis of diagnosis, the sub-markets include blood test, biopsy, imaging tests, ultrasound, computerized tomography (CT) scans, and others. On the basis of route of administration, the sub-markets include oral, parenteral, and others. On the basis of end user, the sub-markets include hospitals, specialty clinics, homecare, and others. On the basis of distribution channel, the sub-markets include hospital pharmacy, retail pharmacy, online pharmacy, and others.
The report provides profiles of the companies in the market such as Bayer AG, Mylan (is now part of Viatris), Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GSK plc, Novartis AG, Zydus Lifesciences Ltd., AstraZeneca, and Johnson & Johnson Services, Inc..
The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the pancreatic cancer market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.
